Company profile VCNX
There is not enough data for Vaccinex - Clinical stage biotech to provide analysis
There is not enough data for Vaccinex - Clinical stage biotech to provide correlation calculation
There is not enough data for Vaccinex - Clinical stage biotech to provide analysis
There is not enough data for Vaccinex login to provide analysis
There is not enough data for Vaccinex login to provide correlation calculation
There is not enough data for Vaccinex login to provide analysis
There is not enough data for Vaccinex pepinemab to provide analysis
There is not enough data for Vaccinex pepinemab to provide correlation calculation
There is not enough data for Vaccinex pepinemab to provide analysis
Google Trends for SEMA4D
Q4 +78.6% YoY, -45.9% QoQ | Q1 +594.0% YoY, +247.0% QoQ | Correlation: 0.34
After 39 days of this quarter the interest is at 38.0. Based on that we can calculate that during remaining 52 days it will total up to 89.0. SEMA4D expected interest is significantly higher compared to previous quarter (+287.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 19 | 89 368.4% QoQ | 98 10.1% QoQ | 67 -31.6% QoQ |
| 2020 | 53 178.9% YoY -20.9% QoQ | 14 -84.3% YoY -73.6% QoQ | 119 21.4% YoY 750.0% QoQ | 53 -20.9% YoY -55.5% QoQ |
| 2021 | 14 -73.6% YoY -73.6% QoQ | 89 535.7% YoY 535.7% QoQ | 35 -70.6% YoY -60.7% QoQ | 166 213.2% YoY 374.3% QoQ |
| 2022 | 74 428.6% YoY -55.4% QoQ | 106 19.1% YoY 43.2% QoQ | 87 148.6% YoY -17.9% QoQ | 17 -89.8% YoY -80.5% QoQ |
| 2023 | 142 91.9% YoY 735.3% QoQ | 49 -53.8% YoY -65.5% QoQ | 82 -5.7% YoY 67.3% QoQ | 23 35.3% YoY -72.0% QoQ |
| 2024 | 38 -73.2% YoY 65.2% QoQ | - | - | - |
The average 5 years interest of SEMA4D was 5.49 per week. The last year interest of SEMA4D compared to the last 5 years has changed by -6.74%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -10.02%.
There is not enough data for Recurrent head and neck cancer study to provide analysis
There is not enough data for Recurrent head and neck cancer study to provide correlation calculation
There is not enough data for Recurrent head and neck cancer study to provide analysis
After 39 days of this quarter the interest is at 62.0. Based on that we can calculate that during remaining 52 days it will total up to 145.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 176 | 91 -48.3% QoQ | 58 -36.3% QoQ | 119 105.2% QoQ |
| 2020 | 53 -69.9% YoY -55.5% QoQ | 55 -39.6% YoY 3.8% QoQ | 131 125.9% YoY 138.2% QoQ | 120 0.8% YoY -8.4% QoQ |
| 2021 | 125 135.8% YoY 4.2% QoQ | 161 192.7% YoY 28.8% QoQ | 72 -45.0% YoY -55.3% QoQ | 81 -32.5% YoY 12.5% QoQ |
| 2022 | 106 -15.2% YoY 30.9% QoQ | 102 -36.6% YoY -3.8% QoQ | 119 65.3% YoY 16.7% QoQ | 264 225.9% YoY 121.8% QoQ |
| 2023 | 167 57.5% YoY -36.7% QoQ | 55 -46.1% YoY -67.1% QoQ | 88 -26.1% YoY 60.0% QoQ | 231 -12.5% YoY 162.5% QoQ |
| 2024 | 62 -62.9% YoY -73.2% QoQ | - | - | - |
The average 5 years interest of Alzheimer's Disease study was 9.33 per week. The last year interest of Alzheimer's Disease study compared to the last 5 years has changed by 5.79%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 6.7%.
There is not enough data for Huntington's disease Phase 3 to provide analysis
There is not enough data for Huntington's disease Phase 3 to provide correlation calculation
There is not enough data for Huntington's disease Phase 3 to provide analysis
There is not enough data for ActivMAb to provide analysis
There is not enough data for ActivMAb to provide correlation calculation
There is not enough data for ActivMAb to provide analysis
There is not enough data for Antibody drug discovery to provide analysis
There is not enough data for Antibody drug discovery to provide correlation calculation
There is not enough data for Antibody drug discovery to provide analysis
After 39 days of this quarter the interest is at 87.0. Based on that we can calculate that during remaining 52 days it will total up to 203.0. Pox viruses expected interest is significantly lower compared to previous quarter (-56.9%) and same quarter last year (-49.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 184 | 129 -29.9% QoQ | 98 -24.0% QoQ | 228 132.7% QoQ |
| 2020 | 446 142.4% YoY 95.6% QoQ | 331 156.6% YoY -25.8% QoQ | 226 130.6% YoY -31.7% QoQ | 180 -21.1% YoY -20.4% QoQ |
| 2021 | 248 -44.4% YoY 37.8% QoQ | 146 -55.9% YoY -41.1% QoQ | 334 47.8% YoY 128.8% QoQ | 261 45.0% YoY -21.9% QoQ |
| 2022 | 331 33.5% YoY 26.8% QoQ | 497 240.4% YoY 50.2% QoQ | 641 91.9% YoY 29.0% QoQ | 311 19.2% YoY -51.5% QoQ |
| 2023 | 402 21.5% YoY 29.3% QoQ | 335 -32.6% YoY -16.7% QoQ | 207 -67.7% YoY -38.2% QoQ | 471 51.4% YoY 127.5% QoQ |
| 2024 | 87 -78.4% YoY -81.5% QoQ | - | - | - |
The average 5 years interest of Pox viruses was 23.34 per week. The last year interest of Pox viruses compared to the last 5 years has changed by 10.07%. The interest for Pox viruses is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 89.18%.
There is not enough data for Vaccinex headquarters. to provide analysis
There is not enough data for Vaccinex headquarters. to provide correlation calculation
There is not enough data for Vaccinex headquarters. to provide analysis